187 related articles for article (PubMed ID: 33459554)
1. [The efficacy of ethylmethylhydroxypyridine succinate in patients with cerebrovascular pathology complicated with diabetes mellitus and metabolic syndrome].
Ekusheva EV; Biryukova EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12):138-143. PubMed ID: 33459554
[TBL] [Abstract][Full Text] [Related]
2. [Chronic cerebrovascular diseases and metabolic syndrome: approaches to pathogenic therapy of cognitive dysfunction].
Tanashyan MM; Lagoda OV; Antonova KV; Konovalov RN
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):106-110. PubMed ID: 28635727
[TBL] [Abstract][Full Text] [Related]
3. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome.
Anfossi G; Russo I; Trovati M
Curr Vasc Pharmacol; 2008 Oct; 6(4):313-28. PubMed ID: 18855719
[TBL] [Abstract][Full Text] [Related]
4. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.
Greenberg AS
J Diabetes Complications; 2003; 17(4):218-28. PubMed ID: 12810246
[TBL] [Abstract][Full Text] [Related]
5. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome.
Rembold CM
Curr Diab Rep; 2004 Oct; 4(5):330-4. PubMed ID: 15461896
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia].
Zhuravleva MV; Prokofiev AB; Serebrova SY; Vasyukova NS; Demchenkova EY; Arkhipov VV
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(6):119-124. PubMed ID: 32678558
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological management of metabolic syndrome.
Rask Larsen J; Dima L; Correll CU; Manu P
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):397-410. PubMed ID: 29345505
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with ischemic stroke].
Zhuravleva MV; Shchukin IA; Fidler MS; Prokofiev AB; Serebrova SY; Vasyukova NS; Demchenkova EY; Arkhipov VV
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12. Vyp. 2):60-66. PubMed ID: 33449535
[TBL] [Abstract][Full Text] [Related]
10. Drug treatment of metabolic syndrome.
Altabas V
Curr Clin Pharmacol; 2013 Aug; 8(3):224-31. PubMed ID: 22950955
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of the diabetic heart.
Tziakas DN; Chalikias GK; Kaski JC
Coron Artery Dis; 2005 Nov; 16 Suppl 1():S3-S10. PubMed ID: 16340402
[TBL] [Abstract][Full Text] [Related]
12. Association Between Metabolic Syndrome and Microvascular and Macrovascular Disease in Type 2 Diabetic Mellitus.
Lee MY; Hsiao PJ; Huang JC; Hsu WH; Chen SC; Shin SJ
Am J Med Sci; 2018 Apr; 355(4):342-349. PubMed ID: 29661347
[TBL] [Abstract][Full Text] [Related]
13. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
López-Jaramillo P; Barbosa E; Molina DI; Sanchez R; Diaz M; Camacho PA; Lanas F; Pasquel M; Accini JL; Ponte-Negretti CI; Alcocer L; Cobos L; Wyss F; Sebba-Barroso W; Coca A; Zanchetti A;
J Hypertens; 2019 Jun; 37(6):1126-1147. PubMed ID: 30882601
[TBL] [Abstract][Full Text] [Related]
14. Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: a systematic review.
Cantiello F; Cicione A; Salonia A; Autorino R; De Nunzio C; Briganti A; Gandaglia G; Dell'Oglio P; Capogrosso P; Damiano R
Int J Urol; 2015 Jan; 22(1):22-32. PubMed ID: 25345683
[TBL] [Abstract][Full Text] [Related]
15. Association of Tourette Syndrome and Chronic Tic Disorder With Metabolic and Cardiovascular Disorders.
Brander G; Isomura K; Chang Z; Kuja-Halkola R; Almqvist C; Larsson H; Mataix-Cols D; Fernández de la Cruz L
JAMA Neurol; 2019 Apr; 76(4):454-461. PubMed ID: 30640363
[TBL] [Abstract][Full Text] [Related]
16. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
17. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Després JP
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous manifestations of diabetes mellitus and the metabolic syndrome.
Karadag AS; Ozlu E; Lavery MJ
Clin Dermatol; 2018; 36(1):89-93. PubMed ID: 29241758
[TBL] [Abstract][Full Text] [Related]
19. [Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment].
Tanashyan MM; Lagoda OV; Antonova KV
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(9):70-75. PubMed ID: 26525819
[TBL] [Abstract][Full Text] [Related]
20. [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].
Vanuzzo D; Pilotto L; Mirolo R; Pirelli S
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):6S-17S. PubMed ID: 18773746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
